Gopi Shankar - Feb 7, 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Development Officer
Signature
By: /s/ Jennifer Johansson, Attorney-in-fact
Stock symbol
LRMR
Transactions as of
Feb 7, 2023
Transactions value $
$0
Form type
4
Date filed
2/9/2023, 04:06 PM
Next filing
Dec 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +180K $0.00 180K Feb 7, 2023 Common Stock 180K $5.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 25% on February 7, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.